Clinical trials: Camrelizumab
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Chordoma, Chemotherapy Effect
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and…
- Trial name
- NCT06140732
- Testing
- camrelizumab and apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Hepatocellular Carcinoma
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR…
- Trial name
- NCT05062837
- Testing
- Hepatectomy Combined With Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Non-small Cell Lung Cancer Metastatic
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer
- Trial name
- IMCORT-2 (NCT05472467)
- Testing
- Camrelizumab, stereotactic body radiation therapy, Chemotherapy
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05085626
- Testing
- fluzoparib+chidamide, fluzoparib+camrelizumab
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast…
- Trial name
- NCT06632405
- Testing
- Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tumor Immunity, Immunosuppression
RFA Plus Carrizumab vs Carrizumab Alone for HCC
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
- Conditions
- Tumor Immunity, Immunosuppression, Radiofrequency Ablation
- Trial name
- NCT04150744
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine